Pfizer is about to lose its top finance executive. According to Endpoints News, chief financial officer Dave Denton will depart the drugmaker in August. BioPharma Dive reports that Denton is leaving for a job outside the pharmaceutical industry, and that a search is already underway for his successor.
The CFO role is one of the most consequential seats at any large drug company. The finance chief steers how a company spends on research, pursues acquisitions, and talks to Wall Street about its results. A departure at Pfizer — and the hunt to replace Denton — lands at a moment when investors are watching the industry's biggest players closely.
The same day brought better news for a rival. Endpoints News and BioPharma Dive both report that GSK won approval for a drug to treat urinary tract infections, a common bacterial infection. New approvals matter because they open the door to sales and give patients and doctors fresh treatment options.
Both outlets also flagged a broader run of activity across the sector. BioPharma Dive notes that Denali Therapeutics sold a regulatory "fast-pass," that a new type of Duchenne gene therapy drew venture backing, and that an earlier GSK deal paid dividends. Endpoints News listed news touching Apellis Pharmaceuticals, Servier, TORL BioTherapeutics, Verastem, Corcept Therapeutics, Legend Biotech, COUR Pharmaceuticals, cAMPfield Therapeutics and LabGenius Therapeutics, though specifics were not detailed in the items provided.
Why it matters: a leadership change at one of the world's largest drugmakers, paired with a fresh approval for a competitor, is a snapshot of how quickly fortunes and talent shift in the pharmaceutical business.